德琪医药-B(06996.HK)：ATG-022联合KEYTRUDA®(帕博利珠单抗)±化疗的IB/II期研究于中国获授予IND批准
ANTENGENEANTENGENE(HK:06996) Ge Long Hui·2025-12-02 08:47

Core Viewpoint - The approval of the investigational new drug (IND) application for ATG-022, a CLDN18.2 antibody-drug conjugate (ADC), by the National Medical Products Administration (NMPA) in China marks a significant advancement for the company in its clinical research efforts [1] Group 1 - The NMPA has approved the IND application for ATG-022 in combination with MSD's KEYTRUDA® (pembrolizumab) [1] - The approval includes the initiation of the Phase Ib/II CLINCH-2 study, which will evaluate the combination of ATG-022 with pembrolizumab and chemotherapy [1]